LGALS3BP and Hepatic fibrosis: Management and treatment of HBV infection in low-income and middle-income countries differs substantially from that in developed countries because of the difficulty in accessing medical resources.6 Measuring serum direct biomarkers, such as Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA-M2BP) and Enhanced Liver Fibrosis score, and performing liver biopsy examination for patients with HBV infection would mean great economic burden in limited health-care budgets.7,8 Simpler and less-expensive methods to evaluate liver fibrosis stage is to be established.